{"url_path":"/sec/mbrx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","accession_number":"0001437749-26-017034","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":569,"has_tables":true,"body_markdown":"mbrx20260331_10q.htm\n\n0001659617\nMoleculin Biotech, Inc.\nfalse\n--12-31\nQ1\n2026\n\n0.001\n0.001\n5,000,000\n5,000,000\n0\n0\n0\n0\n0.001\n0.001\n500,000,000\n500,000,000\n5,336,350\n5,336,350\n3,199,228\n3,199,228\n3\n1\n45\n5\n5\n12\n1\n0\n0\n0\n12,000\nfalse\nfalse\nfalse\nfalse\n\n00016596172026-01-012026-03-31\nxbrli:shares\n00016596172026-05-07\nthunderdome:item\niso4217:USD\n00016596172026-03-31\n00016596172025-12-31\niso4217:USDxbrli:shares\n00016596172025-01-012025-03-31\n00016596172024-12-31\n00016596172025-03-31\n0001659617mbrx:CommonStockOutstandingMember2025-12-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001659617us-gaap:RetainedEarningsMember2025-12-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31\n0001659617mbrx:CommonStockOutstandingMember2026-01-012026-03-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001659617us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31\n0001659617mbrx:CommonStockOutstandingMember2026-03-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001659617us-gaap:RetainedEarningsMember2026-03-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31\n0001659617mbrx:CommonStockOutstandingMember2024-12-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001659617us-gaap:RetainedEarningsMember2024-12-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31\n0001659617mbrx:CommonStockOutstandingMember2025-01-012025-03-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001659617us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31\n0001659617mbrx:CommonStockOutstandingMember2025-03-31\n0001659617us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001659617us-gaap:RetainedEarningsMember2025-03-31\n0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31\nxbrli:pure\n0001659617mbrx:AnimalLifeSciencesIncMember2019-12-31\nutr:Y\n00016596172025-05-232025-05-23\n00016596172025-06-27\n00016596172025-12-15\n0001659617mbrx:ReverseStockSplitMember2025-12-012025-12-01\n0001659617mbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001659617us-gaap:FairValueInputsLevel1Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001659617us-gaap:FairValueInputsLevel2Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001659617us-gaap:FairValueInputsLevel3Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001659617mbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001659617us-gaap:FairValueInputsLevel1Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001659617us-gaap:FairValueInputsLevel2Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001659617us-gaap:FairValueInputsLevel3Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001659617mbrx:WarrantLiabilityLongTermMember2025-12-31\n0001659617mbrx:WarrantLiabilityLongTermMember2026-01-012026-03-31\n0001659617mbrx:WarrantLiabilityLongTermMember2026-03-31\n0001659617srt:ScenarioPreviouslyReportedMember2024-01-01\n00016596172024-01-01\n0001659617srt:ScenarioPreviouslyReportedMember2025-01-012025-03-31\n0001659617srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember2025-01-012025-03-31\n0001659617mbrx:SeriesEAndFWarrantsMember2026-02-19\n0001659617mbrx:SeriesEAndFWarrantsMember2026-02-192026-02-19\n0001659617mbrx:SeriesHWarrantsMember2026-02-19\n0001659617mbrx:SeriesEWarrantsMember2026-02-19\n0001659617mbrx:SeriesFWarrantsMember2026-02-19\n0001659617mbrx:SeriesGWarrantsMember2026-02-19\n0001659617mbrx:SeriesEFHAndGWarrantsMember2026-02-192026-02-19\n0001659617us-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-31\n0001659617us-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-31\n0001659617us-gaap:MeasurementInputPriceVolatilityMember2026-03-31\n0001659617us-gaap:MeasurementInputPriceVolatilityMember2025-12-31\n0001659617us-gaap:MeasurementInputExpectedTermMember2026-03-31\n0001659617us-gaap:MeasurementInputExpectedTermMember2025-12-31\n0001659617us-gaap:MeasurementInputExpectedDividendRateMember2026-03-31\n0001659617us-gaap:MeasurementInputExpectedDividendRateMember2025-12-31\n0001659617mbrx:LiabilityClassifiedWarrantsMember2025-12-31\n0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:WeightedAverageMember2025-12-31\n0001659617mbrx:LiabilityClassifiedWarrantsMember2026-01-012026-03-31\n0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:WeightedAverageMember2026-01-012026-03-31\n0001659617mbrx:LiabilityClassifiedWarrantsMember2026-03-31\n0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:WeightedAverageMember2026-03-31\n0001659617mbrx:The2025AtmAgreementMember2025-07-31\n0001659617mbrx:The2025AtmAgreementMember2025-12-23\n0001659617mbrx:The2025AtmAgreementMember2026-01-012026-03-31\n0001659617us-gaap:SubsequentEventMembermbrx:The2025AtmAgreementMember2026-05-012026-05-14\n0001659617srt:MinimumMemberus-gaap:SubsequentEventMembermbrx:The2025AtmAgreementMember2026-05-14\n0001659617mbrx:SeriesGAndHWarrantsMemberus-gaap:SubsequentEventMember2026-04-30\n0001659617mbrx:SeriesGAndHWarrantsMemberus-gaap:SubsequentEventMember2026-05-14\n0001659617mbrx:GeneralAndAdministrativeExpensesMember2026-01-012026-03-31\n0001659617mbrx:GeneralAndAdministrativeExpensesMember2025-01-012025-03-31\n0001659617mbrx:ResearchAndDevelopmentExpensesMember2026-01-012026-03-31\n0001659617mbrx:ResearchAndDevelopmentExpensesMember2025-01-012025-03-31\n0001659617mbrx:EquityClassifiedWarrantsMember2026-01-012026-03-31\n0001659617mbrx:EquityClassifiedWarrantsMember2025-01-012025-03-31\n0001659617mbrx:EquityClassifiedWarrantsMember2026-03-31\n0001659617mbrx:EquityClassifiedWarrantsMember2025-03-31\n0001659617mbrx:The2024StockPlanMember2026-03-31\n0001659617mbrx:ConsultingAgreementWarrantsMemberus-gaap:SubsequentEventMember2026-05-06\n0001659617mbrx:ConsultingAgreementWarrantsMemberus-gaap:SubsequentEventMember2026-05-062026-05-06\n00016596172023-09-30\n0001659617mbrx:MDAndersonMember2026-01-012026-03-31\n0001659617mbrx:MDAndersonMember2025-01-012025-03-31\n\n \n\n[Table of Contents](#toc)\n\n \n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**☒****QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the quarterly period ended March 31, 2026**\n\nor\n\n**☐****TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the transition period from****                ****to****                **\n\nCommission File Number: 001-37758\n\n**MOLECULIN BIOTECH, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n**Delaware**\n \n**2834**\n \n**47-4671997**\n\n(State or Other Jurisdiction of\n\nIncorporation or Organization)\n \n(Primary Standard Industrial\n\nClassification Code Number)\n \n(IRS Employer\n\nIdentification Number)\n\n \n\n5300 Memorial Drive, Suite 950\n \n\nHouston, TX\n\n**77007**\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\n**713-300-5160**\n\n(Registrant’s telephone number, including area code)\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:\n\n \n\nLarge accelerated filer ☐\n \nSmaller reporting company ☒\n\nNon-accelerated filer ☒\n\nEmerging growth company ☐ \n\nAccelerated filer ☐\n  \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n**Title of each class**\n\n**Trading Symbol (s)**\n\n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.001 per share\n\nMBRX\n\nThe NASDAQ Stock Market LLC\n\n \n\nThe registrant had 5,336,350 shares of common stock outstanding at May 7, 2026.\n\n \n\n \n\n[Table of Contents](#toc)\n\n   \n\n \n\n \n\n**Moleculin Biotech, Inc.**\n\n**Form 10-Q**\n\n**Table of Contents**\n\n** **\n\n \n \n\n**Page**\n\n \n\n[**PART I – FINANCIAL INFORMATION**](#Part1)\n\n[3](#Part1)"}